Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) generates news at the intersection of biotechnology, AI, and cardiovascular medicine. As an artificial intelligence-powered precision cardiovascular medicine company, its announcements often focus on clinical validation of its genetic-epigenetic tests, partnerships with healthcare providers and community organizations, reimbursement milestones, and expansion into new markets.
News coverage for Cardio Diagnostics frequently highlights developments related to its Epi+Gen CHD and PrecisionCHD blood tests for coronary heart disease. Articles include updates on clinical data, such as studies demonstrating PrecisionCHD’s ability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA), as well as research collaborations that explore inflammation-driven CHD and the use of anti-inflammatory medications alongside molecular testing.
Investors and clinicians following CDIO can also expect news about reimbursement and regulatory progress, including gapfill payment rates from the Centers for Medicare and Medicaid Services and the assignment of CPT Proprietary Laboratory Analysis codes. Additional coverage includes provider network expansion across concierge, functional medicine, and primary care practices in multiple U.S. regions, and community health partnerships with organizations such as YMCA of East Tennessee and Southdale YMCA to bring heart health education and advanced testing to local communities.
International and intellectual property developments are another key news theme. Cardio Diagnostics has reported patents in jurisdictions including Japan, which support its global intellectual property strategy, and has announced its first expansion outside the United States through an agreement to launch the PrecisionCHD test in India with Aimil Ltd. and Dr. Lal PathLabs. For readers interested in how AI, epigenetics, and genetics are being applied to coronary heart disease, the CDIO news stream offers ongoing updates on clinical, commercial, and strategic milestones.
Cardio Diagnostics (NASDAQ: CDIO) announced a strategic agreement with Aimil and Dr. Lal PathLabs to launch the PrecisionCHD™ blood test in India. This marks Cardio Diagnostics’ first expansion outside the United States and targets earlier detection and personalized management of coronary heart disease (CHD).
PrecisionCHD combines epigenetics, genetics and AI to detect obstructive and non‑obstructive CHD, including INOCA and MINOCA; supporting data were presented at the American Heart Association Scientific Sessions. Initial integration into Dr. Lal PathLabs’ network (290+ labs, 300+ MD pathologists) has begun, with commercial rollout expected in 2026.
Cardio Diagnostics (Nasdaq: CDIO) announced a community partnership with the Southdale YMCA in Edina, Minnesota to expand heart health education and AI‑powered cardiovascular testing.
Key details: the Southdale YMCA serves ~14,000 members (about 80% adults). Cardio Diagnostics will host an in‑person education session on January 26, 2026 at 11:30 AM CT and participate in the Southdale YMCA Heart Health Fair on February 25, 2026, 8 AM–4 PM CT. Discounted clinician‑ordered tests Epi+Gen CHD (three‑year CHD risk) and PrecisionCHD will be available via telemedicine, at‑home kits, or onsite blood collection.
Cardio Diagnostics (Nasdaq: CDIO) announced that the Centers for Medicare and Medicaid Services (CMS) finalized a $854 gapfill payment rate for both Epi+Gen CHD™ and PrecisionCHD™ tests, effective for dates of service on or after January 1, 2026. The final rate increases from preliminary gapfill rates of $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. Both tests have dedicated CPT PLA codes, 0439U (Epi+Gen CHD) and 0440U (PrecisionCHD), effective April 1, 2024. The company characterized the final rate as a step toward expanding Medicare access to its AI-driven cardiovascular tests.
Cardio Diagnostics (Nasdaq: CDIO) will present data at the American Heart Association Scientific Sessions (New Orleans, Nov 7–10, 2025) showing that its PrecisionCHD epigenetic-genetic blood test can detect INOCA and MINOCA presentations. In a University of Iowa collaboration of 267 hospitalized acute coronary syndrome patients, methylation indices from PrecisionCHD detected INOCA with an overall AUC of 0.90 and provided molecular phenotyping to inform personalized care.
The release notes prior validation in three independent cohorts published in the Journal of the American Heart Association and emphasizes potential use in women, rural patients, telemedicine, and settings lacking invasive provocative testing.
Cardio Diagnostics (Nasdaq: CDIO) is partnering with YMCA of East Tennessee to offer heart‑health education and discounted AI‑powered cardiovascular tests to the Knoxville area.
Programs begin in November 2025 with six "Wisdom Wednesdays" sessions at Tennova and Davis branches; a community Heart Health Fair and on‑site sample collection are planned for February 2026 (American Heart Month). Tests available at a discounted rate include Epi+Gen CHD (3‑year CHD risk) and PrecisionCHD (diagnosis/management); both are physician‑ordered, epigenetics and AI‑based blood tests with at‑home or event collection via a telemedicine platform.
The program targets YMCA’s >40,000 members and the wider East Tennessee community amid elevated state cardiovascular mortality (state: 22.9% of deaths; national: 20.1%).
Cardio Diagnostics (Nasdaq: CDIO) announced it added 15 new provider organizations across the United States on October 21, 2025, expanding adoption of its AI-driven tests Epi+Gen CHD™ and PrecisionCHD™. The new partners span four regions (Northeast, South, Midwest, West) and a range of care models including concierge, functional, longevity, direct primary care, and primary care practices.
By integrating the company's combined epigenetic-genetic and AI testing, providers aim to obtain actionable insights into coronary heart disease and heart attack risk to guide personalized prevention and management.
Cardio Diagnostics (NASDAQ:CDIO) has received preliminary gapfill payment rates from CMS for its AI-powered cardiovascular tests. The rates are set at $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™, effective January 1, 2025.
Both tests received dedicated CPT PLA codes earlier in 2024. PrecisionCHD™ aids in CHD diagnosis through genetic and epigenetic marker analysis, while Epi+Gen CHD™ assesses three-year risk for CHD events. The tests are performed via blood draw, offering non-invasive cardiovascular assessment for Medicare beneficiaries.
These preliminary rates represent a significant milestone in expanding Medicare access to advanced cardiovascular testing, particularly important as heart disease remains the leading cause of death in the US, with over 700,000 American deaths in 2022.Cardio Diagnostics (NASDAQ: CDIO) has entered into an agreement with AGEPHA Pharma to validate a precision-guided approach for treating inflammation-driven coronary heart disease (CHD). AGEPHA will supply LODOCO® (low-dose colchicine), an FDA-approved anti-inflammatory medication, for a clinical study using Cardio Diagnostics' PrecisionCHD™ blood test.
The study will evaluate PrecisionCHD™'s ability to identify patients with inflammation-driven CHD and monitor their response to LODOCO® treatment. The test utilizes AI-powered genetic-epigenetic analysis examining six DNA methylation markers related to modifiable CHD drivers, including inflammation. This initiative aligns with the American Heart Association's $15 million commitment to studying inflammation's impact on cardiovascular health.
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The compliance was achieved after implementing a 1:30 reverse stock split on May 13, 2025, which helped maintain the company's closing bid price above $1.00 per share through May 27, 2025. Nasdaq officially confirmed CDIO's compliance status on May 28, 2025, through a notification letter, considering the matter resolved.
FAQ
What is the current stock price of Cardio Diagnostics Holdings (CDIO)?
What is the market cap of Cardio Diagnostics Holdings (CDIO)?
